P. Coric

发表

New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.

M. Fournié-Zaluski, P. Coric, S. Turcaud, 1994, Journal of medicinal chemistry.

Synthesis and characterization of water-soluble macrocyclic peptides stabilizing protein α-turn.

P. Coric, M. Vidal, S. Bouaziz, 2018, Organic & biomolecular chemistry.

Targeting the proangiogenic VEGF-VEGFR protein-protein interface with drug-like compounds by in silico and in vitro screening.

Sylvain Rault, Maria A Miteva, Bruno O Villoutreix, 2011, Chemistry & biology.

Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site.

P. Coric, S. Turcaud, S. Bouaziz, 2013, European journal of medicinal chemistry.

Characterization of a Novel Type of HIV-1 Particle Assembly Inhibitor Using a Quantitative Luciferase-Vpr Packaging-Based Assay

P. Coric, S. Turcaud, S. DaFonseca, 2011, PloS one.

Expression of novel proteins by polyomaviruses and recent advances in the structural and functional features of agnoprotein of JC virus, BK virus, and simian virus 40

P. Coric, S. Bouaziz, A. S. Saribas, 2018, Journal of cellular physiology.

Pain-suppressive effects on various nociceptive stimuli (thermal, chemical, electrical and inflammatory) of the first orally active enkephalin-metabolizing enzyme inhibitor RB 120

P. Coric, S. Turcaud, B. Roques, 1997, Pain.

Insight into the mechanism of action of EP‐39, a bevirimat derivative that inhibits HIV‐1 maturation

P. Coric, S. Turcaud, S. Bouaziz, 2019, Antiviral research.

Mixed Polymeric Micelles for Rapamycin Skin Delivery

P. Coric, J. Guigner, S. Bouaziz, 2022, Pharmaceutics.

Biophysical Studies of the Induced Dimerization of Human VEGF Receptor 1 Binding Domain by Divalent Metals Competing with VEGF-A

M. Lascombe, P. Coric, M. Reille‐Seroussi, 2016, PloS one.

Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.

M. Fournié-Zaluski, P. Coric, S. Turcaud, 1996, Journal of medicinal chemistry.

Novel approaches in the development of new analgesics

M. Fournié-Zaluski, P. Coric, S. Turcaud, 1990, Neurophysiologie Clinique/Clinical Neurophysiology.

Emerging From the Unknown: Structural and Functional Features of Agnoprotein of Polyomaviruses

P. Coric, J. Condra, M. White, 2016, Journal of cellular physiology.

On-resin cyclization of peptide ligands of the Vascular Endothelial Growth Factor Receptor 1 by copper(I)-catalyzed 1,3-dipolar azide-alkyne cycloaddition.

P. Coric, M. Vidal, S. Bouaziz, 2007, Bioorganic & medicinal chemistry letters.

Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities.

P. Coric, B. Roques, H. Meudal, 2000, Journal of medicinal chemistry.

Aminophosphinic inhibitors as transition state analogues of enkephalin-degrading enzymes: a class of central analgesics.

M. Fournié-Zaluski, P. Coric, B. Roques, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Genuine selective caspase-2 inhibition with new irreversible small peptidomimetics

M. Karin, P. Coric, E. Jacotot, 2021, bioRxiv.

Beta-amino-thiols inhibit the zinc metallopeptidase activity of tetanus toxin light chain.

M. Fournié-Zaluski, P. Coric, B. Roques, 1998, Journal of medicinal chemistry.

Unexpected formation of new chiral 3-amino-5-alkyl-2,5-dihydro-1H-pyrrolin-2-ones from N-Boc-α-amino esters

P. Coric, B. Roques, H. Dhôtel, 2005 .

Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor.

Michel Vidal, Christiane Garbay, P. Coric, 2007, Journal of medicinal chemistry.

"Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes.

F Noble, M. Fournié-Zaluski, P. Coric, 1992, Journal of medicinal chemistry.

CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins

P. Coric, B. Roques, R. Maldonado, 1997, Psychopharmacology.

Assessment of physical dependence after continuous perfusion into the rat jugular vein of the mixed inhibitor of enkephalin-degrading enzymes, RB 101.

M. Fournié-Zaluski, P. Coric, S. Turcaud, 1994, European journal of pharmacology.

RB 101, mixed-inhibitor prodrug of enkephalin-degrading enzymes, intra venously infused in rats does not induce development of physical dependence

M. Fournié-Zaluski, P. Coric, S. Turcaud, 1994, Regulatory Peptides.

Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101.

M. Fournié-Zaluski, P. Coric, B. Roques, 1992, European journal of pharmacology.

Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation.

M. Fournié-Zaluski, P. Coric, S. Turcaud, 1992, Journal of medicinal chemistry.

Synthesis and in vitro activities of new non-peptidic APA inhibitors.

P. Coric, B. Roques, C. Llorens-Cortes, 2008, The journal of peptide research : official journal of the American Peptide Society.

The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain

Pierre Boulanger, P. Coric, S. DaFonseca, 2008, Virology Journal.

Guttiferone A Aggregates Modulate Silent Information Regulator 1 (SIRT1) Activity.

P. Coric, M. Vidal, S. Bouaziz, 2016, Journal of medicinal chemistry.

Synthesis and separation of tritiated inhibitors of aminopeptidase A and their prodrugs

P. Coric, B. Roques, C. Llorens-Cortes, 2004 .

Nuclear Magnetic Resonance Structure Revealed that the Human Polyomavirus JC Virus Agnoprotein Contains an α-Helix Encompassing the Leu/Ile/Phe-Rich Domain

P. Coric, M. White, S. Bouaziz, 2014, Journal of Virology.

Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).

P. Coric, B. Roques, H. Meudal, 2002, Journal of medicinal chemistry.

Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols.

P. Coric, B. Roques, C. Llorens-Cortes, 1994, Journal of medicinal chemistry.

Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors.

P. Coric, B. Roques, C. Llorens-Cortes, 1994, Journal of medicinal chemistry.

Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.

P. Coric, S. Turcaud, B. Roques, 1996, Journal of medicinal chemistry.

The HIV-1 maturation inhibitor, EP39, interferes with the dynamic helix-coil equilibrium of the CA-SP1 junction of Gag.

V. Larue, P. Coric, S. Turcaud, 2020, European journal of medicinal chemistry.

Nuclear Magnetic Resonance Structure of the Human Polyoma JC Virus Agnoprotein

P. Coric, J. Condra, M. White, 2017, Journal of cellular biochemistry.

The 3-O-(3’,3’-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells

Pierre Boulanger, P. Coric, S. DaFonseca, 2007, Antiviral therapy.

Structural studies of the binding of an antagonistic cyclic peptide to the VEGFR1 domain 2.

P. Coric, M. Vidal, S. Bouaziz, 2019, European journal of medicinal chemistry.

NMR Spectroscopy Can Help Accelerate Antiviral Drug Discovery Programs.

P. Coric, T. C. França, Steven R. LaPlante, 2023, Microbes and infection.